PHASE I STUDY OF THE COMBINATION OF CARFILZOMIB AND PANOBINOSTAT FOR PATIENTS WITH RELAPSED AND REFRACTORY MYELOMA: A MULTICENTER MMRC CLINICAL TRIAL

被引：0
|
作者：
Kaufman, J. [1 ]
Zimmerman, T. [2 ]
Jakubowiak, A. [2 ]
Rosenbaum, C. [2 ]
Lewis, C.
Harvey, D. [1 ]
Nooka, A.
Heffner, L. [1 ]
Lonial, Sagar [1 ]
机构：
[1] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P771
引用
收藏
页码：322 / 323
页数：2
相关论文
共 50 条
  • [1] Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
    Kaufman, Jonathan L.
    Zimmerman, Todd
    Rosenbaum, Cara A.
    Nooka, Ajay K.
    Heffner, Leonard T.
    Harvey, R. Donald
    Gleason, Charise
    Lewis, Colleen
    Sharp, Cathy
    Barron, Kenisha W.
    Lonial, Sagar
    [J]. BLOOD, 2014, 124 (21)
  • [2] Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
    Berdeja, Jesus G.
    Hart, Lowell L.
    Mace, Joseph R.
    Arrowsmith, Edward R.
    Essell, James H.
    Owera, Rami S.
    Hainsworth, John D.
    Flinn, Ian W.
    [J]. HAEMATOLOGICA, 2015, 100 (05) : 670 - 676
  • [3] A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).
    Berdeja, Jesus G.
    Gregory, Tara K.
    Matous, Jeffrey
    Hart, Lowell L.
    Owera, Rami
    Mace, Joseph Ronald
    Essell, James H.
    Flinn, Ian
    Faber, Edward Anthony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma
    Lonial, S.
    Francis, D.
    Karanes, C.
    Trudel, S.
    Dollard, A.
    Harvey, D.
    Kaufman, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Francis, Dixil
    Karanes, Chatchada
    Trudel, Suzanne
    Reece, Donna E.
    Krishnan, Amrita
    Buacharem, Marc
    Smith, Renee
    Zaman, Faraz
    Gul, Engin
    Dollard, Akari M.
    Harvey, Donald
    Kaufman, Jonathan
    [J]. BLOOD, 2008, 112 (11) : 1270 - 1270
  • [6] Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
    Manasanch, Elisabet E.
    Shah, Jatin J.
    Lee, Hans C.
    Weber, Donna M.
    Thomas, Sheeba K.
    Amini, Behrang
    Olsem, Jasper
    Crumpton, Brandon
    Morphey, Ashley
    Berkova, Zuzana
    Feng, Lei
    Orlowski, Robert Z.
    [J]. HAEMATOLOGICA, 2020, 105 (05) : E242 - E245
  • [7] A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion
    Berdeja, Jesus G.
    Gregory, Tara B.
    Faber, Edward
    Matous, Jeffrey
    Hart, Lowell
    Mace, Joseph R.
    Arrowsmith, Edward R.
    Flinn, Ian W.
    [J]. BLOOD, 2016, 128 (22)
  • [8] A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Reu, Frederic J.
    Valent, Jason
    Malek, Ehsan
    Sobecks, Ronald M.
    Faiman, Beth M.
    Hamilton, Kimberly
    Elberson, Jamie
    Fada, Sherry
    Liu, Hien K.
    Samaras, Christy
    Smith, Mitchell R.
    [J]. BLOOD, 2015, 126 (23)
  • [9] A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort
    Berdeja, Jesus G.
    Gregory, Tara K.
    Faber, Edward A.
    Hart, Lowell L.
    Mace, Joseph R.
    Arrowsmith, Edward R.
    Flinn, Ian W.
    Matous, Jeffrey V.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : 428 - 435
  • [10] A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma
    Gay, Francesca
    Guenther, Andreas
    Offidani, Massimo
    Engelhardt, Monika
    Schub, Natalie
    Gentili, Silvia
    Montefusco, Vittorio
    Poenisch, Wolfram
    Patriarca, Francesca
    Angelucci, Emanuele
    Astolfi, Monica
    Corradini, Paolo
    Einsele, Hermann
    Sonneveld, Pieter
    Palumbo, Antonio
    Gramatzki, Martin
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E125 - E126
12345